Oct 9
|
Supernus Pharmaceuticals Inc (SUPN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...
|
Sep 24
|
Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree
|
Sep 24
|
Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?
|
Sep 19
|
Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
|
Aug 8
|
Supernus Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations
|
Aug 7
|
Supernus (SUPN) Reports Q2 Earnings: What Key Metrics Have to Say
|
Aug 6
|
Supernus Pharmaceuticals (SUPN) Misses Q2 Earnings Estimates
|
Aug 6
|
Supernus: Q2 Earnings Snapshot
|
Aug 6
|
Supernus Announces Second Quarter 2024 Financial Results
|
Jul 23
|
Supernus Pharmaceuticals to Announce Second Quarter 2024 FinancialĀ Results and Host Conference Call on August 6, 2024
|
May 30
|
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
|
May 24
|
Do Options Traders Know Something About Supernus (SUPN) Stock We Don't?
|
May 10
|
Supernus Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Strategic Shifts and Pipeline ...
|
May 10
|
Supernus Pharmaceuticals First Quarter 2024 Earnings: EPS: US$0.002 (vs US$0.31 in 1Q 2023)
|
May 9
|
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
|
May 9
|
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q1 2024 Earnings Call Transcript
|
May 9
|
Supernus Pharmaceuticals Inc (SUPN) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
|
May 8
|
Compared to Estimates, Supernus (SUPN) Q1 Earnings: A Look at Key Metrics
|
May 8
|
Supernus Announces First Quarter 2024 Financial Results
|
May 7
|
M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for QelbreeĀ® (Viloxazine XR) in Latin America
|